Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CV8Y | ISIN: AU0000148496 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
AUSTRALIAN CLINICAL LABS LIMITED Chart 1 Jahr
5-Tage-Chart
AUSTRALIAN CLINICAL LABS LIMITED 5-Tage-Chart
PR Newswire
257 Leser
Artikel bewerten:
(1)

LabConnect and Australian Clinical Labs' Specialised Trials Announce Strategic Partnership in Australia and Asia Pacific Region

PORT MELBOURNE, Australia and JOHNSON CITY, Tenn., Feb. 24, 2025 /PRNewswire/ -- LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials in Australia and the Asia-Pacific region.

ACL Logo

This exclusive, multi-year agreement solidifies the partnership, and enables both organizations to leverage complementary strengths to help get patients the medicines they need by meeting the growing regional demand of clinical trial support services for pharmaceutical, biotechnology, and clinical research organizations.

ACL Specialised Trials is one of the leading clinical trials laboratories in Australia, managing large biotech and pharmaceutical clinical trials from Phase 1 to Phase 4 studies. With a vast network of laboratories across Australia, ACL Specialised Trials has extensive experience in delivering end to end pathology solutions and a wide range of clinical trials central laboratory services for national, multi-site and single site clinical trial studies.

"This long-term partnership will help global clients access Australian patients and bring key international trials to this part of the world - ultimately resulting in the advancement of leading-edge medical breakthroughs that can save lives and improve patient outcomes," stated ACL Group Executive CEO, Melinda McGrath. "It will strengthen our position as a key player in a growing $8 billion market and I am excited to showcase our depth of experience and talented team on the world stage. This is fantastic news for our communities, and we are proud to be partnering with LabConnect."

As the world's most agile central laboratory solutions partner, LabConnect will leverage ACL's extensive test menu with a comprehensive range of services to support the region including in-country lab kit building, biospecimen management, project and data management, and logistics support. Catherine Osborne, APAC General Manager, leads LabConnect's growing operations and business in the region.

As LabConnect's primary laboratory services provider for Australia and the broader APAC region, ACL Specialised Trials will support LabConnect with their dedicated, clinical trials laboratory and project team situated in Port Melbourne, Victoria, serving as the operational hub for the region.

Wes Wheeler, LabConnect CEO, added, "Our clients increasingly include Asian Pacific investigative sites in their clinical development plans and our partnership with ACLSpecialised Trials provides us with a platform from which we can deliver our comprehensive suite of industry-leading central laboratory services across the region."

About ACL Specialised Trials

Specialised Trials is a subsidiary of Australian Clinical Labs, showcasing our commitment to improving patient lives through medical excellence, market-leading technology and a talented team of experts. ACL Specialised Trials offers a dedicated pathology approach to Phase I-IV clinical trials, delivering quality solutions for our clients. Our state-of-the-art, purpose-built facility and years of experience with commercial and clinical trials ensures a seamless transition from initial inquiry through to delivery.

Visit us at specialisedtrials.com.au
Follow us on LinkedIn

About LabConnect

LabConnect is the world's most agile central laboratory solutions partner, providing technology-driven, customized, orchestrated, and scalable support services for clinical trials of all sizes and complexity. With over 20 years experience and 1,900+ clinical studies across 93 countries, LabConnect is the trusted partner for biotechnology, pharmaceutical, and clinical research organizations.

With modern operations and strategic alliances with world-leading laboratories, LabConnect is uniquely positioned to provide access to the latest innovation and automation. LabConnect delivers exceptional service with a comprehensive suite of central laboratory solutions including custom lab kits, advanced sample tracking and integrated logistics, global standardized sample processing, industry-leading testing menu of 10,200+ validated assays, worldwide support for radiopharmaceuticals, and next-generation biorepository.

LabConnect scientific experts support pre-clinical and clinical studies with scientific project management, bioanalytical and biospecimen management, biomarker strategy and logistics solutions. LabConnect excels at data management, integrating complex datasets from diverse sources into a single, cohesive, submission-ready dataset.

Follow LabConnect on LinkedIn
Learn more at labconnect.com

LabConnect Logo

Photo - https://mma.prnewswire.com/media/2623488/LabConnect_and_Australian_Clinical_Labs_Specialised_Trials_Partnership.jpg
Logo - https://mma.prnewswire.com/media/2611513/LabConnect_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/labconnect-and-australian-clinical-labs-specialised-trials-announce-strategic-partnership-in-australia-and-asia-pacific-region-302381146.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.